๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

โœ Scribed by Stone, John H.; Merkel, Peter A.; Spiera, Robert; Seo, Philip; Langford, Carol A.; Hoffman, Gary S.; Kallenberg, Cees G.M.; St. Clair, E. William; Turkiewicz, Anthony; Tchao, Nadia K.; Webber, Lisa; Ding, Linna; Sejismundo, Lourdes P.; Mieras, Kathleen; Weitzenkamp, David; Ikle, David; Seyfert-Margolis, Vicki; Mueller, Mark; Brunetta, Paul; Allen, Nancy B.; Fervenza, Fernando C.; Geetha, Duvuru; Keogh, Karina A.; Kissin, Eugene Y.; Monach, Paul A.; Peikert, Tobias; Stegeman, Coen; Ytterberg, Steven R.; Specks, Ulrich

Book ID
121402608
Publisher
Massachusetts Medical Society
Year
2010
Tongue
English
Weight
424 KB
Volume
363
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Rituximab versus Cyclophosphamide for AN
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
โœ Stone, John H.; Merkel, Peter A.; Spiera, Robert; Seo, Philip; Langford, Carol A ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 424 KB

## Background: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (anca)-associated vasculitis for 40 years. uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-ba

Rituximab versus Cyclophosphamide in ANC
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
โœ Jones, Rachel B.; Cohen Tervaert, Jan Willem; Hauser, Thomas; Luqmani, Raashid; ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 408 KB

## Background: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (anca)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. treatment with rituximab has led to remission rates of 80 to 90% among